**
In a revealing turn of events, internal records obtained by the Center for Biological Diversity have unveiled meetings between top executives at Bayer and U.S. Environmental Protection Agency (EPA) officials, highlighting potential collusion between the Trump administration and the pesticide giant. The discussions primarily centred around the controversial herbicide glyphosate, known for its association with cancer allegations from thousands of users. This alarming intersection of corporate interests and public health raises critical questions about the integrity of regulatory practices in the U.S.
A Meeting of Minds: Bayer and the EPA
On June 17, 2025, Bayer’s CEO, Bill Anderson, alongside other senior executives, convened with key EPA officials, including Lee Zeldin, the agency’s administrator. The agenda, as outlined in internal emails, was to address “litigation” concerns and explore “supreme court action” regarding glyphosate. This meeting occurred just weeks before the Supreme Court requested input from the Trump administration on whether to hear Bayer’s case, which seeks to limit the company’s liability concerning cancer risks associated with its products.
The stakes are high. Bayer faces numerous lawsuits alleging that glyphosate, the active ingredient in its widely used herbicide Roundup, has caused cancer in users. The company’s strategy hinges on persuading the Supreme Court to endorse its argument that absence of a mandated cancer warning from the EPA absolves it of responsibility.
Trump Administration’s Support for Bayer
Since the June meeting, the Trump administration has taken several actions that appear to favour Bayer’s position. In a December 2025 filing, D John Sauer, the solicitor general appointed by Trump, urged the Supreme Court to hear Bayer’s case, which they subsequently agreed to, scheduling a hearing for April 27, 2026. Furthermore, in February 2026, the White House invoked the Defense Production Act to protect glyphosate production, effectively granting immunity to manufacturers like Bayer.
This pattern of support raises eyebrows among environmental advocates and legal experts alike. Nathan Donley, director of environmental health science at the Center for Biological Diversity, remarked, “The political appointees at the EPA are more concerned with corporate profits than with protecting American health.”
Concerns Over Corporate Influence
Experts are sounding the alarm over the implications of such high-level meetings. Whitney Di Bona, a consumer safety advocate, expressed concern that while Bayer’s executives were able to privately discuss liability with EPA officials, the voices of thousands of individuals who claim to have suffered health consequences from glyphosate were notably absent from the conversation.
Naomi Oreskes, a Harvard professor who studies corporate influence on regulation, noted that this kind of access is emblematic of a troubling trend where industry leaders receive preferential treatment from government officials, sidelining the public’s health and safety concerns.
Zen Honeycutt, founder of Moms Across America, echoed these sentiments, stating that regulatory capture by chemical companies is not a new phenomenon. Her organisation has repeatedly engaged with the EPA, yet they have seen little action on their calls to restrict or ban harmful pesticides.
The Bigger Picture: Regulatory Ethics in Question
Bayer maintains that its interactions with the EPA are standard regulatory procedures, asserting transparency in its position regarding glyphosate. However, the timing and content of these meetings, coupled with subsequent administrative actions, suggest a deeper entanglement between corporate interests and public policy.
The stark contrast in treatment between corporate representatives and affected individuals raises ethical questions about the regulatory framework in the United States. It challenges the very foundation of environmental governance, suggesting that corporate lobbying may overshadow the voices of those most impacted by these products.
Why it Matters
The revelations surrounding Bayer’s influence on the EPA underscore a critical issue: the potential for corporate interests to shape public health policies at the expense of citizen welfare. As the legal battles over glyphosate continue, this situation serves as a cautionary tale about the need for transparency, accountability, and a regulatory system that prioritises the health of the public over corporate profit margins. In a world grappling with the consequences of environmental degradation, the implications of these meetings extend far beyond glyphosate, raising urgent questions about the integrity of our regulatory institutions.
